Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Medicenna Secures Global Patent Grants
Business patent grants

Medicenna Secures Global Patent Grants

Analysis based on 7 articles · First reported Jun 11, 2026 · Last updated Jun 11, 2026

Sentiment
40
Attention
3
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The patent grants strengthen Medicenna Therapeutics' intellectual property, potentially increasing its market value and investor confidence. This development could lead to future revenue streams from its Superkine platforms and clinical programs, positively impacting the biotechnology and pharmaceutical sectors.

biotechnology pharmaceuticals
Event Summary

Medicenna Therapeutics Corp. announced the issuance of two new US patents and the allowance of an additional US patent application, alongside recent grants in Australia and Canada. These patents cover its proprietary IL-4 and IL-13 Superkine platforms, including bizaxofusp, MDNA11, and MDNA113, which are in clinical development for cancer and autoimmune diseases. The new US patents specifically protect cellular immunotherapy applications, immune cell targeting constructs, and bizaxofusp combination therapy for CNS tumors. Medicenna Therapeutics now boasts a global portfolio exceeding 100 active granted patents and applications, reinforcing its intellectual property position in Superkine-based immunotherapy.

Key Actions
70 Medicenna Therapeutics received patent grants
40 United States — National Institutes of Health co-owned patent Medicenna Therapeutics
Entities Involved
stock
Medicenna Therapeutics
Medicenna Therapeutics has strengthened its intellectual property portfolio with new patent grants in the US, Australia, and Canada, covering its Superkine platforms and lead clinical programs. This enhances the company's competitive position and potential for future revenue.
Importance 100 Sentiment 50
cnt
United States
The United States is a key jurisdiction where Medicenna Therapeutics received new patent grants, extending protection for its cellular immunotherapy applications and combination therapies for CNS tumors.
Importance 60 Sentiment 0
cnt
Australia
Australia is one of the jurisdictions where Medicenna Therapeutics received a patent grant for its bizaxofusp formulation for CNS tumors, expanding the geographic reach of its intellectual property.
Importance 30 Sentiment 0
cnt
Canada
Canada is another jurisdiction where Medicenna Therapeutics received a patent grant for its IL-2 Super Agonist and checkpoint inhibitors for cancer treatment, further strengthening its global patent portfolio.
Importance 30 Sentiment 0
govactor
United States — National Institutes of Health
The United States — National Institutes of Health is a co-owner of one of the newly issued US patents, indicating its collaboration with Medicenna Therapeutics on IL-4 Superkine fusion proteins.
Importance 20 Sentiment 0
cnt
China
China is a country where Medicenna Therapeutics has pending patent applications, indicating its efforts to expand intellectual property protection globally.
Importance 10 Sentiment 0
loc
Europe
Europe is a region where Medicenna Therapeutics has granted patents and pending applications, contributing to its global patent estate.
Importance 10 Sentiment 0
cnt
India
India is a country where Medicenna Therapeutics has granted patents and pending applications, extending its intellectual property reach.
Importance 10 Sentiment 0
cnt
Japan
Japan is a country where Medicenna Therapeutics has granted patents and pending applications, contributing to its global patent portfolio.
Importance 10 Sentiment 0
cnt
South Korea
South Korea is a country where Medicenna Therapeutics has pending patent applications, indicating its efforts to expand intellectual property protection globally.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.